Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5665 - MET exon 14 splicing mutation and its correlation with clinocopathological features in subjects with non-small cell lung cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Darko Katalinic

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

D. Katalinic1, I. Aleric2, A. Vcev1

Author affiliations

  • 1 Department Of Clinical Medicine, Faculty of Medicine and Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 - Osijek/HR
  • 2 Department Of Internal Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 - Osijek/HR
More

Resources

Abstract 5665

Background

Driver mutations are genomic alterations important for tumor initiation and growth. They are found in genes that control cellular proliferation and long-term survival. Mesenchymal-to-epithelial transition (MET) exon 14 splicing mutation occurs in about 3% of cases of non-small cell lung cancer (NSCLC). It has been recognized as an important biomarker to predict response to MET tyrosine-kinase inhibitor therapy. The aim of this study was to investigate possible connection among the MET exon 14 mutations and genomic as well as clinicopathological features in patients with NSCLC.

Methods

The study was performed among 270 patients (58% males and 42% females; mean age of 57.14 ± 16.48 years) with histologically confirmed diagnosis of NSCLC. The distribution of MET exon 14 splicing mutation was detected using the quantitative real-time polymerase chain reaction restriction fragment length polymorphism assay. RNA was extracted from formalin-fixed paraffin-embedded samples. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.

Results

MET exon 14 splicing mutation was detected in 9 patients (3.4%). It was found in 7 adenocarcinomas (18.9%) and in 2 squamous cell carcinomas (5.4%). Most adenocarcinomas occurred in females and non-smokers. Squamous cell carcinoma predominantly occurred in male smoking patients. All subjects with MET exon 14 splicing mutation had earlier pathology stage of disease (IA, IB, IIA, IIB) (31%) and older age (>75 years) (43%). Overall survival (OS) of these patients were statistically longer than in patients with KRAS and EGFR mutations (2.2 vs. 1.3 months and 2.4 vs. 1.8 months).

Conclusions

We found that MET exon 14 splicing mutation occurs at a frequency of 3.4%, in older age, and mostly in early stage of NSCLC. OS of patients harboring MET exon 14 splicing mutation has lasted longer than in patients harboring KRAS and EGFR mutations. Patients with MET exon 14 splicing mutation may respond well to MET tyrosine-kinase inhibitor therapy. Further studies are needed to confirm our results.

Clinical trial identification

Legal entity responsible for the study

Cancer Genomic Group.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings